PSMA ligands for PET imaging of prostate cancer

Journal of Nuclear Medicine

Volumn 58, Issue 10, 2017, Pages 1545-1552

  Schwarzenboeck, Sarah M ^a   Rauscher, Isabel ^b   Bluemel, Christina ^c   Fendler, Wolfgang P ^d,e   Rowe, Steven P ^f   Pomper, Martin G ^f   Asfhar Oromieh, Ali ^g,h   Herrmann, Ken ^d,i   Eiber, Matthias ^b,d  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

PET CT; Prostate cancer; PSMA

Indexed keywords

LIGAND; PROSTATE SPECIFIC MEMBRANE ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ADVANCED CANCER; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER STAGING; DIAGNOSTIC VALUE; EVIDENCE BASED PRACTICE; HUMAN; IMAGE DISPLAY; METASTASIS; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING; DIAGNOSTIC IMAGING; IMAGE PROCESSING; MALE; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIGANDS; MALE; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 85030867019     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.117.191031     Document Type: Article

References (96)

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends: an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16-27.
2. Heesakkers RA, Hovels AM, Jager GJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9: 850-856.
3. Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387-395.
4. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122-2127.
5. Turkbey B, Brown AM, Sankineni S, Wood BJ, Pinto PA, Choyke PL. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J Clin. 2016;66:326-336.
6. Filson CP, Natarajan S, Margolis DJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016;122:884-892.
7. Schöder H, Herrmann K, Gonen M, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostatespecific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11: 4761-4769.
8. Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40(suppl 1):S5-S10.
9. Souvatzoglou M, Weirich G, Schwarzenboeck S, et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17:3751-3759.
10. Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63:1040-1048.
11. Fanti S, Minozzi S, Castellucci P, et al. PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43:55-69.
12. Buchegger F, Garibotto V, Zilli T, et al. First imaging results of an intraindividual comparison of 11C-acetate and 18F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:68-78.
13. Nanni C, Schiavina R, Boschi S, et al. Comparison of 18F-FACBC and 11Ccholine PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging. 2013;40(suppl 1): S11-S17.
14. Nanni C, Schiavina R, Brunocilla E, et al. 18F-FACBC compared with 11Ccholine PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer. 2014;12:106-110.
15. Nanni C, Schiavina R, Brunocilla E, et al. 18F-fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med. 2015;40:e386-e391.
16. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
17. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Path Oncol Res. 2009;15:167-172.
18. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256-2261.
19. Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552-558.
20. Budäus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69:393-396.
21. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436-1443.
22. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6 (suppl 10):S13-S18.
23. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol. 2006;3:216-225.
24. Rajasekaran SA, Anilkumar G, Oshima E, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14:4835-4845.
25. Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-539.
26. Commandeur LC, Parsons JR. Degradation of halogenated aromatic compounds. Biodegradation. 1990;1:207-220.
27. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
28. Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-697.
29. Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-ofconcept human studies. J Nucl Med. 2015;56:1169-1176.
30. Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostatespecific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-1891.
31. Rowe SP, Gage KL, Faraj SF, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56: 1003-1010.
32. Rowe SP, Macura KJ, Mena E, et al. PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411-419.
33. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678-688.
34. Eiber MFW, Rowe SP, Calais J, et al. PSMA ligands for imaging and therapy. J Nucl Med. In press.
35. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41: 11-20.
36. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18Ffluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185-1190.
37. Schwenck J, Rempp H, Reischl G, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:92-101.
38. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
39. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
40. Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44: 1258-1268.
41. Meredith G, Wong D, Yaxley J, et al. The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016;118(suppl 3):49-55.
42. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926-937.
43. Rowe SP, Macura KJ, Ciarallo A, et al. Comparison of prostate-specific membrane antigen-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naive and castration-resistant metastatic prostate cancer. J Nucl Med. 2016;57:46-53.
44. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18F]DCFPyL and [68Ga] Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575-584.
45. Dietlein F, Kobe C, Neubauer S, et al. PSA-stratified performance of 18F- and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58:947-958.
46. Herlemann A, Wenter V, Kretschmer A, et al. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70:553-557.
47. Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/ computerized tomography. Prostate. 2015;75:1934-1940.
48. Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114-2121.
49. van Leeuwen PJ, Emmett L, Ho B, et al. Prospective evaluation of 68galliumprostate-specific membrane antigen positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119:209-215.
50. Fendler WP, Schmidt DF, Wenter V, et al. 68Ga-PSMA PET/CT detects the location and extent of primary prostate cancer. J Nucl Med. 2016;57:1720-1725.
51. Rahbar K, Weckesser M, Huss S, et al. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016;57:563-567.
52. Zamboglou C, Drendel V, Jilg CA, et al. Comparison of 68Ga-HBED-CC PSMAPET/ CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics. 2017;7:228-237.
53. Eiber M, Weirich G, Holzapfel K, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829-836.
54. Ceci F, Castellucci P, Nanni C, Fanti S. PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2103-2104.
55. Schwarzenböck SM, Eiber M, Kundt G, et al. Prospective evaluation of [11C] choline PET/CT in therapy response assessment of standardized docetaxel firstline chemotherapy in patients with advanced castration refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2105-2113.
56. Hillier SM, Kern AM, Maresca KP, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011;52:1087-1093.
57. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334.
58. Murphy G, Ragde H, Kenny G, et al. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 1995;15:1473-1479.
59. Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol. 2012;41:2087-2092.
60. Meller B, Bremmer F, Sahlmann CO, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66.
61. Ahmadzadehfar H, Schlenkhoff CD, Rogenhofer S, Yordanova A, Essler M. 68Ga-PSMA-11 PET represents the tumoricidal effect of 223Ra in a patient with castrate-resistant metastatic prostate cancer. Clin Nucl Med. 2016;41: 695-696.
62. Ahmadzadehfar H, Eppard E, Kurpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488.
63. Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006-1013.
64. Heck MM, Retz M, D'Alessandria C, et al. Systemic radioligand therapy with 177Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016; 196:382-391.
65. Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014;2:273-285.
66. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007;14:531-547.
67. Afshar-Oromieh A, Babich JW, Kratochwil C, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57(suppl):79S-89S.
68. Rowe SP, Drzezga A, Neumaier B, et al. Prostate-specific membrane antigentargeted radiohalogenated PET and therapeutic agents for prostate cancer. J Nucl Med. 2016;57(suppl):90S-96S.
69. Albisinni S, Artigas C, Aoun F, et al. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int. December 15, 2016 [Epub ahead of print].
70. Bluemel C, Linke F, Herrmann K, et al. Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res. 2016;6:78.
71. Dewes S, Schiller K, Sauter K, et al. Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol. 2016;11:73.
72. Shakespeare TP. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Radiat Oncol. 2015;10:233.
73. Sterzing F, Kratochwil C, Fiedler H, et al. 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34-41.
74. van Leeuwen PJ, Stricker P, Hruby G, et al. 68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117: 732-739.
75. Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57:1713-1719.
76. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigenradioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530-534.
77. Rauscher I, Düwel C, Wirtz M, et al. Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int. 2017;120:40-47.
78. Robu S, Schottelius M, Eiber M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017;58:235-242.
79. Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014-1024.
80. Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58:750-755.
81. Schmuck S, Nordlohne S, von Klot CA, et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:960-968.
82. Wondergem M, van der Zant F, Knol R, Lazarenko S, Pruim J, de Jong IJ. 18FDCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes; detection rate, image quality, activity kinetics and biodistribution. J Nucl Med. April 27, 2017 [Epub ahead of print].
83. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697-1705.
84. Pfister D, Porres D, Heidenreich A, et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMAHBED-CC than with 18F-fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:1410-1417.
85. Sahlmann CO, Meller B, Bouter C, et al. Biphasic 68Ga-PSMA-HBED-CC-PET/ CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:898-905.
86. Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. 68Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16:14.
87. Artigas C, Alexiou J, Garcia C, et al. Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:195-196.
88. Kanthan GL, Coyle L, Kneebone A, Schembri GP, Hsiao E. Follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41:500-501.
89. Kobe C, Maintz D, Fischer T, Drzezga A, Chang DH. Prostate-specific membrane antigen PET/CT in splenic sarcoidosis. Clin Nucl Med. 2015;40:897-898.
90. Pyka T, Weirich G, Einspieler I, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med. 2016;57:367-371.
91. Rischpler C, Maurer T, Schwaiger M, Eiber M. Intense PSMA-expression using 68Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging. 2016;43:193-194.
92. Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS. Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin Nucl Med. 2016;41:83-85.
93. Sasikumar A, Joy A, Nanabala R, Pillai MR, Thomas B, Vikraman KR. 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:795-796.
94. Schwenck J, Tabatabai G, Skardelly M, et al. In vivo visualization of prostatespecific membrane antigen in glioblastoma. Eur J Nucl Med Mol Imaging. 2015;42:170-171.
95. Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622-1623.
96. Krohn T, Verburg FA, Pufe T, et al. [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210-214.